Clinical Trial

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Study acronym: LUPARPED
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-18; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2024-10-17
Trial Details
NCT Number NCT06607692
Lead Sponsor Fundación de investigación HM
Conditions Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumours (NET) +14 more
Enrollment 25 participants
Start Date 2024-09-20
Primary Completion 2029-07 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-04